How ipamorelin triggers growth hormone secretion
A short, plain-English walk through the receptor it binds, the pulse it creates, and why it earned the "clean GHRP" label.
TL;DR
- Ipamorelin is a selective ghrelin-receptor mimic that prompts a short pulse of growth hormone release from the pituitary.
- Unlike older GHRPs, it did not meaningfully raise cortisol in published animal studies.
- Ipamorelin has no FDA approval, and long-term human data are limited.
What it is
Ipamorelin is a five-amino-acid peptide built to act like ghrelin — the hormone the stomach releases when it is empty. Ghrelin is famous as the hunger signal. It also has a less-famous job: knocking on the pituitary gland's door to ask for a small pulse of growth hormone (GH). In animal studies, ipamorelin imitated that knock without the cortisol rise seen with older copies.
How it works
Think of the pituitary as a control room with two doorbells. One doorbell is the GHRH receptor — pressed by sermorelin and CJC-1295. The other is the GHSR-1a receptor (in plain English: the ghrelin docking site). Ipamorelin presses the GHSR-1a button. When it does, the pituitary releases a short pulse of GH (Raun et al., European Journal of Endocrinology, 1998). In normal physiology, the body's own feedback loop — somatostatin, the "stop" signal — ends each GH pulse.
Who asks about it
People come to this topic when they have heard ipamorelin called the "clean" growth-hormone peptide and want to know what that actually means. It is often compared with GHRP-6 and GHRP-2, two earlier peptides that also raise GH but bring along extra effects on appetite, prolactin, and cortisol.
What the research says
Published studies, mostly in animals, show ipamorelin produces measurable GH peaks with little cortisol or prolactin rise. That selectivity is the headline finding (Raun et al., Eur J Endocrinol, 1998). Long-term human outcome data is still limited; most evidence is short-duration and pharmacology-focused.
What to know
Ipamorelin is not FDA-approved. As of September 14, 2026, it is not in any FDA 503A category and is not on the 503A bulks list. Reported side effects in the literature include injection-site irritation and brief flushing. Its long-term safety in people has not been established.
The Halftime POV
The "clean GHRP" framing is fair but easy to over-promise on. Ipamorelin's real distinction is selectivity, not magic. Selectivity in animal studies is a real finding; it is not proof of benefit or long-term safety in people.
Related reading:
- Ipamorelin: what this GHRP peptide is
- Ipamorelin research: published evidence reviewed
- Ipamorelin side effects: what the literature reports
- The growth hormone axis explained
FAQ
Q: How does ipamorelin work? A: Ipamorelin is a selective ghrelin-receptor agonist. It mimics the body's hunger hormone at the GHSR-1a docking site on the pituitary gland, prompting a short pulse of growth hormone release.
Q: Why is ipamorelin called a "clean" GHRP? A: Older growth-hormone-releasing peptides like GHRP-6 also raised cortisol and appetite. In animal studies, ipamorelin did not raise cortisol, which is the main basis for the 'clean' label.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved.
Sources
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
How does ipamorelin work?
Ipamorelin is a selective ghrelin-receptor agonist. It mimics the body's hunger hormone at the GHSR-1a docking site on the pituitary gland, prompting a short pulse of growth hormone release.
Why is ipamorelin called a 'clean' GHRP?
Older growth-hormone-releasing peptides like GHRP-6 also raised cortisol and appetite. In animal studies, ipamorelin did not raise cortisol, which is the main basis for the 'clean' label.
